Abstract: A fluid dispensing device includes a housing and a reciprocating piston fluid pump coupled to the housing. The reciprocating piston fluid pump includes a piston. The piston is configured to pressurize at least one pumping chamber. A motor is connected to the reciprocating piston fluid pump to actuate the piston. A spray tip connected to an outlet of the at least one pumping chamber.

Abstract: A fluid dispensing device includes a housing and a reciprocating piston fluid pump coupled to the housing. The reciprocating piston fluid pump includes a piston. The piston is configured to pressurize at least one pumping chamber. A motor is connected to the reciprocating piston fluid pump to actuate the piston. A spray tip connected to an outlet of the at least one pumping chamber.

Abstract: A nanocomposite includes at least one polymer and metal oxide nanoparticles dispersed in the at least one polymer. Each polymer can have a number average molecular weight of at least 10000 grams/mole. The at least one polymer includes a first polymer including (meth)acrylic acid monomer units. The metal oxide nanoparticles are surface modified with a carboxylic acid silane surface modifying agent. An aqueous dispersion that can be used to make the nanocomposite and a method of making the nanocomposite is described.

Abstract: A fluid dispensing device includes a housing and a reciprocating piston fluid pump coupled to the housing. The reciprocating piston fluid pump includes a piston disposed within a cylinder. The piston is configured to pressurize at least one pumping chamber. A motor is coupled to the housing and connected to the reciprocating piston fluid pump to actuate the piston. A wobble assembly connects the motor to the piston of the reciprocating piston fluid pump. A spray tip connected to an outlet of the at least one pumping chamber.

Abstract: Apparatuses, components and methods are provided herein useful to provide assistance to customers and/or workers in a shopping facility. In some embodiments, a shopping facility personal assistance system comprises: a plurality of motorized transport units located in and configured to move through a shopping facility space; a plurality of user interface units, each corresponding to a respective motorized transport unit during use of the respective motorized transport unit; and a central computer system having a network interface such that the central computer system wirelessly communicates with one or both of the plurality of motorized transport units and the plurality of user interface units, wherein the central computer system is configured to control movement of the plurality of motorized transport units through the shopping facility space based at least on inputs from the plurality of user interface units.

Abstract: A nanocomposite includes at least one polymer and metal oxide nanoparticles dispersed in the at least one polymer. Each polymer can have a number average molecular weight of at least 10000 grams/mole. The at least one polymer includes a first polymer including (meth)acrylic acid monomer units. The metal oxide nanoparticles are surface modified with a carboxylic acid silane surface modifying agent. An aqueous dispersion that can be used to make the nanocomposite and a method of making the nanocomposite is described.

Abstract: A display film includes a transparent glass layer having a thickness of 250 micrometers or less, or in a range from 25 to 100 micrometers. A transparent energy dissipation layer is fixed to the transparent glass layer. The transparent energy dissipation layer has a glass transition temperature of 27 degrees Celsius or less and a Tan Delta peak value of 0.5 or greater, or from 1 to 2.

Abstract: The present disclosure provides pharmaceutical compositions that include one or more selective estrogen receptor modulator(s) (SERM(s), e.g., Lasofoxifene) and four or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be able to form nanodroplets (e.g., by self-nanoemulsifying) in vaginal fluid and to deliver the one or more SERM(s) to the vagina of a female subject. The pharmaceutical compositions may be useful in treating or preventing vulvovaginal atrophy, dyspareunia, sexual dysfunction, osteoporosis, or breast cancer in a female subject.

Abstract: The present disclosure provides pharmaceutical compositions that include one or more selective estrogen receptor modulator(s) (SERM(s), e.g., Lasofoxifene) and four or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be able to form nanodroplets (e.g., by self-nanoemulsifying) in vaginal fluid and to deliver the one or more SERM(s) to the vagina of a female subject. The pharmaceutical compositions may be useful in treating or preventing vulvovaginal atrophy, dyspareunia, sexual dysfunction, osteoporosis, or breast cancer in a female subject.

Abstract: A wire reel holder and dispensing assembly is provided for transporting, holding, and dispensing wire from a wire reel. The holder and assembly includes an elongated shaft configured for insertion through a wire reel. Each of a pair of end members has a polygonal outer perimeter edge and a central opening. The shaft is slidably insertable through the central opening of each end member positioning the end members at each end of the wire reel. Each end member is securable to the shaft to hold the wire reel in a static position along a length of the shaft and prevent rolling of the wire reel on the shaft. A holding assembly is provided for connecting the shaft, end members and wire reel to a vehicle.

Abstract: A wire reel holder and dispensing assembly is provided for transporting, holding, and dispensing wire from a wire reel. The holder and assembly includes an elongated shaft configured for insertion through a wire reel. Each of a pair of end members has a polygonal outer perimeter edge and a central opening. The shaft is slidably insertable through the central opening of each end member positioning the end members at each end of the wire reel. Each end member is securable to the shaft to hold the wire reel in a static position along a length of the shaft and prevent rolling of the wire reel on the shaft. A holding assembly is provided for connecting the shaft, end members and wire reel to a vehicle.

Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in treating female sexual dysfunction and the use of an estrogen agonist/antagonist for the manufacture of a medicament for the treatment of female sexual dysfunction. The compositions are comprised of an estrogen agonist/antagonist as a first active ingredient and a cyclic guanosine 3?,5?-monophosphate elevator as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

Abstract: A load moving system includes a pair of lifting assemblies. The assemblies are positioned on opposite sides of a load to be carried. Each of the assemblies includes a plate. A vertical wall is attached to the plate and the plate extends forward from a bottom edge of the vertical wall. The plate is extendable under the load and the vertical wall is positionable against the load. An upper wall is attached to an upper portion of the vertical wall and extends rearward of the vertical wall. A pair of wheel assemblies is provided. Each of the wheel assemblies is positioned below and is rotatably coupled to the upper wall. A pair of support posts is attached to and extends upwardly from the upper wall. A coupling assembly releasably couples the support posts to the load.

Abstract: This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist/antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of assessing vaginal health.

Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in treating female sexual dysfunction and the use of an estrogen agonist/antagonist for the manufacture of a medicament for the treatment of female sexual dysfunction. The compositions are comprised of an estrogen agonist/antagonist as a first active ingredient and a cyclic guanosine 3?,5?-monophosphate elevator as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

Abstract: Pharmaceutical combination compositions including certain estrogen agonists/antagonists and prostaglandins or prostaglandin agonists/antagonists. The compositions are useful for the treatment of bone disorders including osteoporosis.

Abstract: The present invention relates to pharmaceutical compositions, kits and methods comprising combinations of (?)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacologically acceptable acid addition salts thereof and estrogens. The present invention also relates to pharmaceutical compositions, kits and methods comprising combinations of (?)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacologically acceptable acid addition salts thereof, estrogens and progestins.

Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.

Abstract: The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I wherein the variables A, B, Y, D, Z1, G and e are as described herein.

Abstract: This invention relates to methods, pharmaceutical compositions and kits useful in promoting bone formation and/or preventing bone loss and lowering blood cholesterol. The compositions are comprised of an estrogen agonist/antagonist as a first active component and a statin as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.